Subtype
Esophageal and Gastroesophageal Junction Carcinoma
CI-CAN-00002608Explore in graph →
460 active trials11 approved drugs34 evidence items
- NCIt
- C203673
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00002608Explore in graph →
Clinical trials
1,309 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (120)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03623737 | Comparing Paclitaxel/Cisplatin and Cisplatin/5-fluorouracil in Neo-CRT for ESCC | unknown | Phase 2 / Phase 3 | 248 | National Taiwan University HospitalOTHER | 1 | Jun 7, 2022 | clinicaltrials |
| NCT05269056 | Early Detection of Gastric Cancer Using Plasma Cell-free DNA Fragmentomics | unknown | — | 300 | Zhejiang Cancer HospitalOTHER | 1 | Jun 2, 2022 | clinicaltrials |
| NCT05394415 | Chemoradiation Plus Tislelizumab for Conversion Therapy of Locally Nonresectable ESCC(LATE) | unknown | Phase 1 / Phase 2 | 30 | Jiangsu Cancer Institute & HospitalOTHER | 1 | May 27, 2022 | clinicaltrials |
| NCT05381636 | Esophageal Arterial Infusion Chemotherapy Versus Systemic Intravenous Chemotherapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma: a Prospective, Multicentre, Randomised Controlled Clinical Study | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | May 19, 2022 | clinicaltrials |
| NCT02781285 | Effect Study of Clinical Outcomes of Traditional Chinese Medicine to Advanced Gastric Cancer by Propensity Score(ESCOTCMAGCPS) | unknown | — | 1,500 | Shanghai University of Traditional Chinese MedicineOTHER | 1 | May 6, 2022 | clinicaltrials |
| NCT05342389 | Camrelizumab Combined With Apatinib Versus Apatinib Alone in the Third-line Treatment of Metastatic Gastric Cancer | unknown | Phase 2 | 68 | Sixth Affiliated Hospital, Sun Yat-sen UniversityOTHER | 1 | Apr 22, 2022 | clinicaltrials |
| NCT04675866 | Camrelizumab Combined With Albumin-bound Paclitaxel and S-1 in the Treatment of Advanced Gastric Cancer | unknown | N/A | 46 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05319392 | Transcriptomic Signatures in Gastric Adenocarcinoma(GAC) | unknown | — | 48 | Sanjay Gandhi Postgraduate Institute of Medical SciencesOTHER_GOV | 1 | Apr 15, 2022 | clinicaltrials |
| NCT05315830 | A Study of HER2 Tumor Vaccine in Patients With Her-2 Positive Gastric/GEJ Adenocarcinoma Esophagogastric | unknown | Phase 1 | 10 | The First Affiliated Hospital of Bengbu Medical UniversityOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT05322499 | Phase II Clinical Study of Camrelizumab Combined With Chemotherapy or Anlotinib in Advanced Esophageal Squamous Cell Cancer | unknown | Phase 2 | 80 | Zhejiang Cancer HospitalOTHER | 1 | Apr 11, 2022 | clinicaltrials |
| NCT05317325 | A Translational Study of Tumor Antigen-pulsed DC Vaccine for ESCC | unknown | Phase 1 | 20 | Sichuan UniversityOTHER | 1 | Apr 7, 2022 | clinicaltrials |
| NCT05313906 | RC48 Plus AK105 and Cisplatin in Advanced Gastric Cancer | unknown | Phase 2 | 40 | Henan Cancer HospitalOTHER_GOV | 1 | Apr 6, 2022 | clinicaltrials |
| NCT05311189 | Study of HLX10, Trastuzumab and Chemotherapy in First-line Treatment of HER2-positive Recurrent/Metastatic Gastric Cancer | unknown | Phase 2 | 40 | Shanghai Zhongshan HospitalOTHER | 0 | Apr 5, 2022 | clinicaltrials |
| NCT05287880 | Quantitative Analysis of 18F-FAPI Dynamic PET/CT for Accurate Differential Diagnosis of MLN of ESCC | unknown | — | 60 | Fifth Affiliated Hospital, Sun Yat-Sen UniversityOTHER | 0 | Mar 18, 2022 | clinicaltrials |
| NCT04390958 | Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Cisplatin and Capecitabine for Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 70 | Chinese Academy of Medical SciencesOTHER | 1 | Mar 15, 2022 | clinicaltrials |
| NCT05270889 | Study to Evaluate the Safety and Efficacy of Tislelizumab in Combination With Zanidatamab as a 2nd Line in HER2-Positive Advanced Gastric Cancer in K-Umbrella Trial | unknown | Phase 2 | 50 | Yonsei UniversityOTHER | 1 | Mar 8, 2022 | clinicaltrials |
| NCT03917966 | The Phase II Trial of SHR-1210 Combined With Preoperative Chemotherapy or Apatinib for Locally Advanced ESCC | unknown | Phase 2 | 80 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Mar 4, 2022 | clinicaltrials |
| NCT05265962 | Decitabine Plus Penpulimab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 85 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Mar 4, 2022 | clinicaltrials |
| NCT03221400 | PEN-866 in Patients With Advanced Solid Malignancies | unknown | Phase 1 / Phase 2 | 340 | Tarveda TherapeuticsINDUSTRY | 1 | Feb 17, 2022 | clinicaltrials |
| NCT04177797 | Toripalimab With Neoadjuvant Chemotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 20 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Feb 9, 2022 | clinicaltrials |
| NCT05208775 | A Comparative Study of Endoscopic Submucosal Dissection and Photodynamic Therapy for Early Esophageal Cancer | unknown | N/A | 46 | The First Affiliated Hospital of Henan University of Science and TechnologyOTHER | 0 | Jan 26, 2022 | clinicaltrials |
| NCT05199649 | Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora | unknown | N/A | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Jan 20, 2022 | clinicaltrials |
| NCT05174325 | Effectiveness of Neoadjuvant Chemotherapy Combined With PD-1 Monoclonal Antibody in the Treatment of Operable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 30 | The First Affiliated Hospital of Soochow UniversityOTHER | 1 | Dec 30, 2021 | clinicaltrials |
| NCT05007145 | PD-1 Inhibitor Combined With Neoadjuvant Chemotherapy in Subjects With Resectable Locally Advanced Thoracic Esophageal Squamous Cell Carcinoma(REVO) | unknown | Phase 2 | 92 | Fujian Cancer HospitalOTHER_GOV | 1 | Dec 21, 2021 | clinicaltrials |
| NCT05165602 | Evaluation of HER2-targeted Therapy for Gastric Cancer and Establishment and Verification of Monitoring System | unknown | — | 30 | Peking UniversityOTHER | 1 | Dec 21, 2021 | clinicaltrials |
| NCT04506138 | Camrelizumab in Combination With Neoadjuvant Chemotherapy for Resectable Thoracic Esophageal Squamous Cell Carcinoma | unknown | Phase 1 / Phase 2 | 46 | Zhejiang Cancer HospitalOTHER | 1 | Dec 14, 2021 | clinicaltrials |
| NCT02915432 | The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC | unknown | Phase 1 / Phase 2 | 401 | Shanghai Junshi Bioscience Co., Ltd.OTHER | 1 | Dec 13, 2021 | clinicaltrials |
| NCT05130684 | Neo-NTP-CRT for Locally Advanced ESCC(Neo-NTP-CRT) | unknown | Phase 2 | 43 | National Taiwan University HospitalOTHER | 1 | Nov 23, 2021 | clinicaltrials |
| NCT05103501 | Salvage Immunotherapy and Chemotherapy in Esophageal Squamous Cell Carcinoma Patients Nonresponding to Initial Neoadjuvant Chemoradiotherapy(SINCERE) | unknown | Phase 2 | 54 | Shanghai Chest HospitalOTHER | 0 | Nov 2, 2021 | clinicaltrials |
| NCT05071755 | Gastrectomy Outcomes in Elderly Patients(GOE) | unknown | — | 350 | Marmara UniversityOTHER | 1 | Oct 19, 2021 | clinicaltrials |
| NCT05070598 | Camrelizumab Combined With Chemotherapy in First-line Treatment of HER2-positive Gastric Cancer | unknown | Phase 2 | 35 | Shengjing HospitalOTHER | 1 | Oct 7, 2021 | clinicaltrials |
| NCT05044728 | Exploration of Immunodynamic Monitoring in the Population Evaluation of Neoadjuvant Chemotherapy Immunotherapy in Patients With Solid Tumors of the Chest. | unknown | Phase 2 | 80 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Sep 16, 2021 | clinicaltrials |
| NCT03800953 | The Ave-CRT Study for Newly Diagnosed Metastatic Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 26 | National Taiwan University HospitalOTHER | 1 | Sep 8, 2021 | clinicaltrials |
| NCT03387904 | Study of Anlotinib Plus Irinotecan in Patients With Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 120 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Sep 2, 2021 | clinicaltrials |
| NCT04514835 | A Phase Ⅱ Trials of Sintilimab as Consolidation Therapy After Radical Concurrent Chemoradiotherapy in Locally Advanced Unresectable ESCC | unknown | Phase 2 | 44 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 25, 2021 | clinicaltrials |
| NCT04063683 | Paclitaxel and DDP Combined With Anlotinib in the First-line Treatment for Patients With Advanced Esophageal Squamous Cell Carcinoma（ESCC）. | unknown | Phase 2 | 47 | Henan Cancer HospitalOTHER_GOV | 1 | Aug 24, 2021 | clinicaltrials |
| NCT04533490 | A Phase Ⅱ Clinical Trial of Camrelizumab for Adjuvant Treatment of Resectable Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 42 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Aug 23, 2021 | clinicaltrials |
| NCT04888403 | Exploring the Safety and Effectiveness of Toripalimab Combined With Neoadjuvant Radiotherapy and Chemotherapy in the Locally Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Aug 23, 2021 | clinicaltrials |
| NCT04890392 | Tislelizumab Combined With S-1 Plus Oxaliplatin as a Neoadjuvant Treatment in Patients With GC/GEJC | unknown | Phase 2 | 20 | Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyOTHER | 1 | Aug 12, 2021 | clinicaltrials |
| NCT04993378 | Prospectively Predict the Efficacy of Treatment of Gastrointestinal Tumors Based on Peripheral Multi-omics Liquid Biopsy | unknown | — | 40 | Shen LinOTHER | 1 | Aug 6, 2021 | clinicaltrials |
| NCT04984018 | Chidamide Plus Camrelizumab as Second-line Therapy for Advanced ESCC Treated With PD-1 Blockade | unknown | Phase 2 | 73 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 0 | Jul 30, 2021 | clinicaltrials |
| NCT04973475 | Indocyanine Green Tracer Using in Laparoscopic Distal Gastrectomy for Early Gastric Cancer | unknown | Phase 2 | 180 | Fujian Medical UniversityOTHER | 1 | Jul 22, 2021 | clinicaltrials |
| NCT04880811 | Afatinib Plus Toripalimab in Previously Treated ESCC With EGFR Overexpression or EGFR Amplification | unknown | Phase 2 | 43 | Peking UniversityOTHER | 1 | Jul 13, 2021 | clinicaltrials |
| NCT03766178 | Study of Anti-PD-1 Antibody SHR-1210 Plus Nimotuzumab in the Treatment of Advanced Esophageal Squamous Cell Carcinoma | unknown | Phase 2 | 45 | The First Affiliated Hospital of Zhengzhou UniversityOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT04275986 | Concurrent Chemoradiotherapy After Endoscopic Resection for Stage I Esophageal Carcinoma | unknown | Phase 2 | 56 | Chinese Academy of Medical SciencesOTHER | 1 | Jul 7, 2021 | clinicaltrials |
| NCT03713749 | Robotic-assisted Esophagectomy vs. Video-Assisted Thoracoscopic Esophagectomy(REVATE) Trial | unknown | N/A | 212 | Chang Gung Memorial HospitalOTHER | 1 | Jul 1, 2021 | clinicaltrials |
| NCT04851132 | Radiotherapy Plus Durvalumab in Elderly Esophageal Squamous Cell Carcinoma | unknown | N/A | 33 | Chinese Academy of Medical SciencesOTHER | 1 | Jun 22, 2021 | clinicaltrials |
| NCT04915807 | Real-world Data (RWD) of Ramucirumab Plus Paclitaxel | unknown | — | 222 | Hallym University Medical CenterOTHER | 1 | Jun 7, 2021 | clinicaltrials |
Data updated 23 days agoSource updated Jun 7, 2022source: clinicaltrials